1001 related articles for article (PubMed ID: 17224000)
1. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
2. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
3. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
4. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
[TBL] [Abstract][Full Text] [Related]
5. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
[TBL] [Abstract][Full Text] [Related]
6. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
7. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
Hung YJ; Lin SH; Pei D; Kuo SW; Hsieh CH; He CT; Hsing Lee C; Fan SC; Sheu WH
Metabolism; 2006 Apr; 55(4):439-44. PubMed ID: 16546473
[TBL] [Abstract][Full Text] [Related]
9. Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers.
Abdin AA; Baalash AA; Hamooda HE
J Diabetes Complications; 2010; 24(3):168-78. PubMed ID: 19328014
[TBL] [Abstract][Full Text] [Related]
10. [Effects of glimepiride and metformin on free fatty acid in patients with Type 2 diabetes mellitus].
Tang JZ; Mao JP; Yang ZF; Zhou ZG; Tang WL; Feng Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):631-4. PubMed ID: 16114544
[TBL] [Abstract][Full Text] [Related]
11. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin.
Derosa G; Salvadeo SA; D'Angelo A; Fogari E; Ragonesi PD; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
Arch Med Res; 2008 May; 39(4):412-9. PubMed ID: 18375253
[TBL] [Abstract][Full Text] [Related]
13. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.
Bermúdez V; Cano R; Cano C; Bermúdez F; Leal E; Acosta K; Mengual E; Arraiz N; Briceño C; Gómez J; Bustamante M; Aparicio D; Cabrera M; Valdelamar L; Rodriguez M; Manuel V; Hernández R
Am J Ther; 2008; 15(4):409-16. PubMed ID: 18645347
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes.
Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K
Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
17. Increased levels of tumour necrosis factor-alpha (TNF-alpha) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction.
Nyström T; Nygren A; Sjöholm A
Clin Sci (Lond); 2006 Jun; 110(6):673-81. PubMed ID: 16466346
[TBL] [Abstract][Full Text] [Related]
18. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Stocker DJ; Taylor AJ; Langley RW; Jezior MR; Vigersky RA
Am Heart J; 2007 Mar; 153(3):445.e1-6. PubMed ID: 17307426
[TBL] [Abstract][Full Text] [Related]
20. Independent anti-inflammatory effect of insulin in newly diagnosed type 2 diabetes.
Mao XM; Liu H; Tao XJ; Yin GP; Li Q; Wang SK
Diabetes Metab Res Rev; 2009 Jul; 25(5):435-41. PubMed ID: 19405039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
